'Undruggable' cancers slowed by targeting growth signals

(University of California - San Francisco) As many as 50 percent of human cancer cases -- across a wide variety of tissues -- involve defects in a common cellular growth signaling pathway. These defects have so far defied most attempts to develop targeted therapies. Now researchers at UCSF and Redwood City-based Revolution Medicines Inc. have identified a new strategy for potentially treating intractable cancers by decoupling the entire RAS/MAP Kinase (MAPK) signaling pathway from external growth signals.
Source: EurekAlert! - Biology - Category: Biology Source Type: news